MAR 17, 2020 8:00 AM PDT

Multiplexing on Mouse tissue using Cell Signaling Technology antibodies and OPAL IHC method

Speakers

Event Date & Time
DATE:  March 17, 2020
TIME:  8:00am PT, 11:00am PT
Abstract
The determination of target specificity in immunohistochemical analysis requires multiple validation steps. Traditionally, multiplexed immunohistochemistry has been limited to 3 or 4 markers, and cross-reactivity of antibodies can be problematic. Working with murine tissue can present its own set of unique challenges.
 
This webinar will cover the variety of techniques used at Cell Signaling Technology to facilitate antibody validation for both single and multiplex applications, the importance of species-specific validation in immunohistochemistry and the advantages of using rabbit monoclonal antibodies with mouse tissues. We’ll also discuss the advances in multiplex IHC using Opal and rabbit primary antibodies developed by CST to reliably stain for 6 markers in a mouse model of breast cancer and how Akoya Bioscience’s Phenoptics platform can provide quantitative analysis of tumor biology in context.
 
Learning Objectives:
  • Learn to develop Opal IHC Multiplexing strategies on murine tissue regardless of species and without concern for cross-reactivity.
  • Why antibody validation techniques are exceptionally important in multiplex assays and why no single assay is sufficient to verify antibody specificity.
  • The importance of species-specific validation in immunohistochemistry and the advantages of using rabbit monoclonal antibodies with mouse tissues.
  • How Phenoptics with spectral unmixing can remove autofluorescence, produce quantifiable data, and analyze spatial relationships across different species types.
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

 


Connect with us